Merrion Pharmaceuticals, Inc. Is Issued a United States Drug Delivery System Patent
Posted on: Wednesday, 13 July 2005, 09:01 CDT
Merrion Pharmaceuticals, Inc., a specialty pharmaceutical company with novel approaches to oral drug delivery, is pleased to announce the issuance of United States Patent No. 6,780,846, "Membrane translocating peptide drug delivery system." This patent covers new peptide compounds which can be physically or chemically complexed with an active substance, either a drug or a biological, in order to improve delivery across biological membranes.
The ability of these drug-peptide complexes to cross biological membranes such as the epithelium of the gastro-intestinal tract, is enhanced considerably over the ability of the active substance alone. Using such complexes to improve the delivery of a drug to a specific target tissue both enhances the efficacy and reduces the side effects of the drug. Finally, this delivery technology can also be used to enable the oral administration of compounds that are normally administered only as injectables.
According to Thomas Leonard, PhD, Chief Scientific Officer, Merrion Pharmaceuticals, Inc., "These peptide complexes have been demonstrated to improve the delivery of therapeutic peptides and other macromolecules across the gastro-intestinal tract, and to improve the delivery of DNA to cells." Dr. Leonard further adds, "I am pleased that we continue to gain patent protection for our proprietary delivery technologies. The continued growth of our patent estate, further establishes us as one of the leading companies in oral drug delivery."
About Merrion:
Established in 2004, Merrion Pharmaceuticals, Inc. is a privately held international specialty pharmaceutical company, applying advanced drug delivery technologies for the life cycle management of existing drugs, and for enabling the commercialization of biotechnology products. Merrion (www.merrionpharma.com) is focused on novel, oral drug delivery solutions to improve product performance and patient compliance. The company develops and manufactures leading-edge technologies to meet the growing needs of the pharmaceutical and biotechnology industries. Merrion's worldwide headquarters are in Wilmington, NC. The company's R & D and manufacturing operations, Merrion BioPharma Ltd., are located in Dublin, Ireland.
Source: Business Wire
Related Articles
- Patent Challenges Reduce Pharmaceutical Innovation, Productivity
- Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
- House Vote Set Wednesday on First Major Prescription Drug Safety Improvements in Nearly Half Century
- XLHealth's Care Improvement Plus Teams Up With Outcomes Pharmaceutical Healthcare to Improve Medication Compliance Among Chronically Ill Seniors
- A Number of High Value Drugs Due to Come Off Patent in the USA and Europe Over the Next Few Years Are Injectable
- Drug Companies Anticipate Losses As Patent Protections Wear Out
- FzioMed Receives NIH Grant to Study Injectable Delivery of Bone Growth Peptides for Spinal Fusion
- Improving the Oral Health of Prisoners to Improve Overall Health and Well-Being
- Review: Atypical Antipsychotic Drugs Modestly Improve Neuropsychiatric Symptoms of Dementia/COMMENTARY
- BioAlliance Pharma Announces Publication Demonstrating Potential of Miconazole Lauriad Bioadhesive Buccal Tablets to Provide Improved Antifungal Drug Exposure in the Oral Cavity
 |
 |
User Comments (0)
RSS Feeds